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a b s t r a c t
Cardiac resynchronization therapy (CRT) has become a standard option for patients with severe low
cardiac function and mild to severe heart failure. However, its potential has not been maximized to date,
as the optimal atrioventricular delay, ventriculoventricular (VV) delay, and tachy therapy settings remain
unknown. Here, data from various studies have been used to estimate several CRT settings.
Three search words—interventricular interval, VV delay, and interventricular delay with cardiac
resynchronization therapy—were entered into PubMed. The methods used to optimize VV delay
included ultrasonography, radioisotope diagnosis, scintigraphy, electrocardiography, Swan–Ganz cathe-
terization, and thoracic impedance. Their populations and results were analyzed to identify convincing
rules. Methods for VV delay optimization in the literature can be categorized into four patterns. Time and
cost were high in several categories. Most studies concluded that their method was effective but no
small amount of papers denied individual detailed optimization. There were some population biases in
most papers. Individual optimization had a major impact in patients with ischemic heart disease but no
signiﬁcant impact in patients with non-ischemic heart diseases.
In summary, CRT is an established therapy, but a well-controlled study is required to ﬁnd conclusive
methods for VV delay optimization.
& 2014 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.
Contents
1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 413
1.1. Cardiac resynchronization therapy (CRT) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 413
1.2. Categorization of VV delay optimization methods. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 414
2. Methods and results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 414
3. Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 414
Conﬂict of interest. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 415
Acknowledgment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 415
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 415
1. Introduction
Heart failure is a very common life-threatening disease that
incurs a high cost. Therapy for heart failure is important because it
not only improves patients' quality of life and prognosis but may
also prevent subsequent hospitalization and reduce social medical
costs. Optimal therapy for heart failure is needed from both the
social and individual perspectives.
1.1. Cardiac resynchronization therapy (CRT)
CRT is ﬁrmly established but has many areas in need of improve-
ment [1–12]. Particularly, the prognostic value to predict who
responds to CRT is not well established [13–19]. Only QRS duration
has a conﬁrmed value, the sensitivity of which is insufﬁcient,
however [20–22]. The cost of CRT, although more economically
reasonable than other therapies, is high; hence, a more effective
method to predict responders needs to be established.
In addition, the ideal CRT optimization method is unknown
[23]. There are several effective methods, but one has yet to be
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identiﬁed as the best [24–28]. Especially regarding VV delay, there
are many conﬂicting methods and theories [29–31].
1.2. Categorization of VV delay optimization methods
Methods to optimize VV delay remain competitive; therefore,
four categories were created in which to summarize them. The
ﬁrst category focuses on wall motion and dyssynchrony using
ultrasonography, scintigraphy, and other techniques [2,3,32–48].
The second category focuses on conduction delays and disorders
using electrocardiography and a calculation of lead-to-lead con-
duction delay time (time between right ventricular pacing and left
ventricular sensing and between left ventricular pacing and right
ventricular sensing), an electroanatomic mapping system, and
other techniques [22,49–63]. The third category considers cardiac
output estimated by Swan–Ganz catheterization, thoracic impe-
dance, ultrasonography, and other techniques [55,57,58,64–70].
The fourth category eliminates individual optimization and uses a
standard value because these methods acknowledge no major
differences in VV delay settings [3,35,71–82].
Since CRT is pacing therapy, it may correct conduction delays but
does not improve muscle function. Accordingly, the second category
was most appropriate, but most major methods use ultrasonogra-
phy and a majority of papers in this area claim method efﬁcacy. This
may be why we did not want to improve conduction delays; rather,
our aim was to relieve heart failure symptoms by increasing cardiac
output. The third category matched this aim but in many cases
required extensive time and cost. And we decide optimal settings at
rest, which may not be optimal during activity time. We do not
know whether optimal settings at rest improve a patient's activity
and prognosis or not. The fourth category solves this problem: if
optimization is not required, it may be the best option.
The ﬁrst step of this systematic review was determining the
need for optimization, followed by identifying the best method to
optimize the VV delay.
2. Methods and results
A literature search using the PubMed/Medline databases and
consensus documents was performed. Searches using “interven-
tricular interval” found 43 studies, “VV delay” found 59 studies,
and “interventricular delay” found 200 studies of CRT.
In each study, optimization need, associated methods, optimi-
zation modality, and populations were counted. Whenever possi-
ble, optimization need as well as method and modality superiority
was decided objectively (e.g., the measurement of velocity time
integral was not better than the measurement of QRS duration).
A total of 33 studies conﬁrmed the need for optimization and
clearly described the superiority of a detailed optimization. These
studies used the velocity time integral measured by ultrasonogra-
phy, the spectrum of wall motion, dyssynchronicity, nuclear ima-
ging, electrocardiography, and other methods. Their superiority was
proven by both the instant outcome and the clinical results.
Five studies denied the need for optimization. The nominal
settings, including a ﬁxed VV delay (LV4RV of 40 ms or LV¼RV),
met the clinical purpose. They tended not to measure small details,
perhaps since optimal settings change in different situations and
small details are of little consequence. If the clinical output is
unchanged, there is no need to optimize the VV delay.
Seven studies partially afﬁrmed the need for optimization by
removing a detailed check and programing the calculations using
pre-populated generator programing (e.g., Quick Opt, St. Jude
Medical, Inc.)
The use of ultrasonographic cardiography, the most common
modality, for optimization was recommended by 25 studies. The
estimation of cardiac output using velocity time integral measure-
ments was most common. Conduction disorders and ventricular
muscle dyssynchrony were also improved by spectral measure-
ments, septal wall motion delays, and other techniques.
Ten studies emphasized the importance of conduction delays
and stated that electrocardiography was a superior method. In fact,
the smallest QRS duration was determined using electrocardio-
graphy. There is clear evidence that a wide QRS complex is a
prognostic factor of CRT, but it is not clear whether a narrow QRS
pacing is preferable.
Seven studies stated that the use of pre-populated programing
is both necessary and sufﬁcient. Clinically speaking, it met the
demand, but it was unable to obtain the best settings. Therefore,
its use might be sufﬁcient for clinical situations.
The ability to obtain a detailed understanding of cardiac
function using Swan–Ganz catheterization, thoracic impedance,
and other methods has been proven, but few studies have proven
their superiority; rather, they stated that cardiac output was
changed by VV delay but did not determine its inﬂuence on
clinical output [65,68].
The populations of these studies had various biases. Despite
relatively slight differences in age, sex, and QRS duration, in some
studies, 480% of patients had ischemic heart disease, whereas in
others, 470% of patients had non-ischemic heart disease.
The majority of these studies concluded that their particular
method was effective, but most denied that their method was
individual, detailed, and had universal optimization. In most
studies, the population tended to be weighted in one direction.
Individual optimization had some impact in patients with
ischemic heart disease but no major impact in patients with
non-ischemic heart disease.
In the present study, the effect of population bias was particu-
larly considered. A number of papers that argued that a detailed
VV delay optimization improves heart failure contained a large
proportion of patients with ischemic heart disease. On the other
hand, many papers that claimed that detailed optimization was
not important contained a large proportion of patients with non-
ischemic heart disease. Hence, it is possible that a detailed VV
delay optimization was effective in patients with ischemic heart
disease and not needed in patients with non-ischemic heart
disease.
CRT is a therapy for conduction disorders. Damaged cardio-
myocytes are localized in ischemic heart disease; therefore, in a
way, the presence of a conduction disorder is localized and varies
among the cases. On the other hand, conduction disorders were
not always unequal in patients with non-ischemic heart disease.
Localized and inhomogeneous conduction disorders require indi-
vidualized conduction therapy with CRT, whereas diffuse conduc-
tion disorders require only standard settings.
3. Conclusion
CRT is a ﬁrmly established therapy, but we do not yet know
how to maximize its potential at minimum cost. CRT is a costly
therapy; hence, its potential should be fully utilized. We should
also determine routine CRT settings because its use is becoming
more common and an increasing number of CRT devices will be
implanted in the future.
Here, VV delay settings, which are very common but controver-
sial, were particularly noted. Upon examining the study ﬁndings, a
therapy for conduction disorder indicated from the conduction
perspective may be decided by conduction delay dispersion.
Conduction disorders were localized and inhomogeneous in
patients with ischemic heart disease, in whom CRT efﬁcacy was
slightly low; therefore, detailed optimization using echocardiography,
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radioisotopes, Swan–Ganz catheterization, and other methods should
be carefully performed as needed [83,84].
Dilated cardiomyopathy (DCM) has a relatively homogeneous
diffuse conduction order. Clinically simultaneous biventricular
pacing was the most common setting for DCM patients. In the
future, we can determine the indication for optimization according
to speciﬁc diseases or heart conditions.
Here, methods for interventricular delay optimization were
categorized into four groups. The ﬁrst category emphasized wall
motion and dyssynchrony and used ultrasonography. If dyssyn-
chrony was judged to be high, VV delay optimization using
ultrasonography was needed. The second focused heavily on
conduction delays and disorders using electrocardiography. If the
QRS duration was very wide or had a left bundle branch block
pattern, VV delay optimization was needed. Signal-averaged elec-
trocardiography was also useful, but the meaning of its results was
uncertain [85]. The third category placed great weight on cardiac
output. In patients with very low cardiac output, conduction
disorders tended to be high and diffuse and not require optimiza-
tion. Similarly, in the fourth category, heart disease in which a
diffuse conduction disorder was implied did not require optimiza-
tion. In any case, the need for VV delay optimization might be
judged according to a speciﬁc disease or conduction disorder
pattern; hence, the most effective and least costly settings should
be identiﬁed.
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